Phaseline

Companies › Applied Biology

Applied Biology: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Immunology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DA-020
Topical alpha-1 adrenergic agonist
ADRA1APhase 1Chemotherapy Induced AlopeciaFeb 2027
Hyperforin
TRPC channel activator and plant extract with anti-inflammatory properties
TRPC6Phase 1Chemotherapy Induced AlopeciaFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07397325DA-020Phase 1Chemotherapy Induced AlopeciaImmunologyFeb 2027
NCT07397325HyperforinPhase 1Chemotherapy Induced AlopeciaImmunologyFeb 2027

Targets

ADRA1A (1) TRPC6 (1)

Companies with the same targets

Santen SAS Berlin-Chemie AG Menarini Group ARS Pharmaceuticals Opus Genetics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.